Could Temperamental Features Modulate Participation in Clinical Trials?
Alzheimer’ disease
clinical trials
mild cognitive impairment
recruitment
subjective cognitive decline
temperament
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
28
12
2022
revised:
25
01
2023
accepted:
31
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
The prodromal stages of Alzheimer's disease (AD) are the primary focus of research aimed at slowing disease progression. This study explores the influence of affective temperament on the motivation of people with mild cognitive impairment (MCI) and subjective cognitive decline (SCD) to participate in clinical trials. One hundred four subjects with MCI and SCD were screened for participation in pharmacological and non-pharmacological trials. Affective temperament was assessed based on the Temperament Evaluation of the Memphis, Pisa, Paris and San Diego (TEMPS) scale. Demographic variables and temperament subscales scores were compared between MCI and SCD patients and among patients participating in the pharmacological trial, the non-pharmacological trial and refusing participation. Twenty-one subjects consented to participate in the pharmacological trial, seventy consented to the non-pharmacological trial and thirteen refused to participate in any trial. Patients with SCD had greater education and more depressive temperamental traits than those with MCI. While older age, higher education and anxious temperament were negatively associated with participation in the pharmacological trial, irritable temperamental positively predicted pharmacological trial participation. In conclusion, temperamental features may affect the willingness of patients with MCI and SCD to take part in clinical trials and, especially, the choice to participate in pharmacological studies.
Identifiants
pubmed: 36769768
pii: jcm12031121
doi: 10.3390/jcm12031121
pmc: PMC9917573
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Affect Disord. 2010 Aug;124(3):314-8
pubmed: 20417972
J Postgrad Med. 2003 Apr-Jun;49(2):109-13
pubmed: 12867683
J Am Geriatr Soc. 2004 Feb;52(2):263-8
pubmed: 14728638
J Gerontol B Psychol Sci Soc Sci. 2004 Jan;59(1):P4-6
pubmed: 14722332
J Affect Disord. 2020 Jan 1;260:458-462
pubmed: 31539680
Psychopharmacol Bull. 1987;23(1):68-73
pubmed: 3602332
BMJ Open Qual. 2022 Oct;11(4):
pubmed: 36316063
J Affect Disord. 2010 Jan;120(1-3):207-12
pubmed: 19327844
J Pers. 2013 Oct;81(5):452-64
pubmed: 23126563
J Psychosom Res. 2009 Feb;66(2):155-9
pubmed: 19154858
Gerontologist. 2003 Feb;43(1):62-72
pubmed: 12604747
J Affect Disord. 2017 Aug 15;218:339-345
pubmed: 28494392
Psychopharmacol Bull. 2007;40(4):99-115
pubmed: 18227781
Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S
pubmed: 11189689
J Child Adolesc Psychopharmacol. 2020 Nov;30(9):542-548
pubmed: 32882144
Int J Geriatr Psychiatry. 2008 Jan;23(1):95-101
pubmed: 17879254
Neurology. 2018 Jan 16;90(3):126-135
pubmed: 29282327
Rev Neurol (Paris). 2012 Jun;168(6-7):471-82
pubmed: 22579080
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Womens Health (Larchmt). 2014 Aug;23(8):681-7
pubmed: 25046058
Alzheimers Dement. 2013 Sep;9(5):562-71
pubmed: 23159045
J Am Geriatr Soc. 1994 Jan;42(1):1-4
pubmed: 8277103
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
J Affect Disord. 2003 Jan;73(1-2):87-98
pubmed: 12507741
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Nurs Res. 2021 Jul-Aug 01;70(4):289-297
pubmed: 33883501
Alzheimers Dement. 2016 Jul;12(7):796-804
pubmed: 26852195
Arch Gen Psychiatry. 1975 Dec;32(12):1569-73
pubmed: 1200775
Psychiatry Res. 2018 Mar;261:473-480
pubmed: 29360052
Brain Sci. 2022 Nov 15;12(11):
pubmed: 36421878
J Affect Disord. 1998 Jan;47(1-3):1-10
pubmed: 9476738
Ann Neurol. 2021 Jun;89(6):1221-1225
pubmed: 33704823
Neurology. 2018 Jul 24;91(4):e300-e312
pubmed: 29959257
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):325-38
pubmed: 23558480
Am J Geriatr Psychiatry. 2008 Jul;16(7):603-11
pubmed: 18591580
J Affect Disord. 2013 Sep 5;150(2):634-8
pubmed: 23481608
J Intern Med. 2014 Mar;275(3):214-28
pubmed: 24605806
Alzheimers Res Ther. 2017 Oct 4;9(1):81
pubmed: 28978335
Neurology. 2013 Jul 30;81(5):487-500
pubmed: 23897875
Neurology. 2012 Oct 9;79(15):1570-7
pubmed: 22972644
J Alzheimers Dis. 2011;26 Suppl 3:321-9
pubmed: 21971471
Int J Gynecol Cancer. 2015 Oct;25(8):1519-25
pubmed: 26222482
Dement Geriatr Cogn Disord. 2006;22(5-6):471-85
pubmed: 17047326
Neurobiol Aging. 2015 Dec;36(12):3152-3162
pubmed: 26422359
Alzheimers Dement. 2022 Apr;18(4):700-789
pubmed: 35289055
PLoS One. 2016 Jul 20;11(7):e0159664
pubmed: 27438465
Int J Clin Pharmacol Ther. 2008 Mar;46(3):109-18
pubmed: 18397681
J Affect Disord. 2013 Feb 15;145(1):106-10
pubmed: 22884231
Alzheimers Dement. 2014 Jan;10(1):93-8
pubmed: 23562429
Alzheimers Dement (Amst). 2019 Mar 08;11:248-256
pubmed: 30911599
BMJ Open. 2017 Oct 5;7(10):e016071
pubmed: 28982813
Ethn Dis. 1999 Autumn;9(3):333-40
pubmed: 10600055
Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):501-10
pubmed: 15066912
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Geriatr Psychiatry Neurol. 1993 Apr-Jun;6(2):105-11
pubmed: 8512626
J Alzheimers Dis. 2015;49(2):547-60
pubmed: 26484902
Cancer Detect Prev. 2006;30(1):24-33
pubmed: 16495020
J Alzheimers Dis. 2011;23(3):443-52
pubmed: 21116048
Br J Cancer. 2014 Aug 26;111(5):970-5
pubmed: 24983363
Mol Neurodegener. 2020 Sep 22;15(1):55
pubmed: 32962744
J Affect Disord. 1998 Oct;51(1):7-19
pubmed: 9879799
Eur Rev Med Pharmacol Sci. 2013;17(15):2065-79
pubmed: 23884828